September 2nd 2025
Supported by Phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.
August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
August 29th 2025
New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.
August 22nd 2025
New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.
August 22nd 2025
STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.
Identifying Risks for Mortality Among Nursing Home Residents with COVID-19
January 10th 2021Increased age, male sex and underlying health conditions including diabetes and kidney disease were associated with a higher risk of all-cause mortality among nursing home patients with COVID-19, a new study found.
Read More
2 Commerce Drive
Cranbury, NJ 08512